Ticker LaunchReverse merger · Completed · YARW
Yarrow Bioscience, Inc.
Reverse merger with VYNE Therapeutics Inc. (VYNE)
Yarrow Bioscience, Inc. merged into VYNE Therapeutics Inc. (VYNE), a Nasdaq-listed pharmaceutical company, in a reverse merger that takes the private company public. The deal was announced on Dec 17, 2025 and closed on Jul 27, 2026. The combined company trades as Yarrow Bioscience, Inc. (YARW) on Nasdaq.
Yarrow Bioscience is a clinical-stage biotechnology company developing YB-101, an anti-TSHR antibody being studied in Graves' disease and thyroid eye disease. Dosing in a Phase 2a/2b Graves' disease trial began after the merger closed.
- Status
- Completed
- Private company
- Yarrow Bioscience, Inc.
- Public company
- VYNE Therapeutics Inc. (VYNE)
- Public company business before
- Nasdaq-listed pharmaceutical company
- Announced
- Dec 17, 2025
- Closed
- Jul 27, 2026
- Combined company
- Yarrow Bioscience, Inc. (YARW)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Announcement press release
- Closing 8-K Jul 28, 2026
- Closing press release
- All filings on EDGAR CIK 1566044
Other completed reverse mergers
- Obsidian Therapeutics, Inc.into Galera Therapeutics, Inc. · Aug 3, 2026
- Light Across, Inc.into Sharing Economy International Inc. · Aug 2, 2026
- Lōkahi Therapeuticsinto Glucotrack, Inc. · Jul 14, 2026
- Avid Gold Ltdinto Nu-Med Plus, Inc. · Jul 8, 2026
- House of Dogeinto Brag House Holdings, Inc. · Jun 30, 2026
- Aeternum Health LLCinto Shorepower Technologies Inc. · Jun 30, 2026